Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($1.19), versus ($1.01) reported last year. Revenue for the quarter came in at $296 thousand, versus $222 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays sees global expansion intact, warns against market complacency
- Trip.com Group Limited (TCOM) PT Lowered to $65 at Benchmark
- McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
